Skip to content

Home
About Us
- Board of Directors
- Management Team
Technology
News/Resources
Investor Centre
Contacts

ASX Announcements 2016

23 Nov 2016
Results of Annual General Meeting
23 Nov 2016
Presentation to Annual General Meeting
17 Oct 2016
Annual Report & Notice of AGM
17 Oct 2016
Appendix 4C
5 Oct 2016
Director’s Interests – Appendix 3Y
5 Oct 2016
New Issue Announcement – Appendix 3B
5 Sep 2016
Clarification Statement
2 Sep 2016
Option Expiry Notice
22 Aug 2016
Zika Virus Program Update
8 Aug 2016
Appendix 4E Preliminary Final Report
8 Aug 2016
Appendix 4G and Corporate Governance Statement
15 Jul 2016
New Issue Announcement Appendix 3B
8 Jul 2016
Appendix 4C
7 Jul 2016
New Issue Announcement – Appendix 3B
23 May 2016
Biotron Compounds Demonstrate Activity Against Zika Virus
4 May 2016
Presentation at Biotech Invest 2016
20 Apr 2016
R&D Tax Incentive
20 Apr 2016
Appendix 4C
12 Apr 2016
Shareholder Update
17 Mar 2016
Biotron Phase 2 Hepatitis C Trial Success
26 Feb 2016
Half-year report 31 December 2015
18 Feb 2016
Data Indicates BIT225 May Have a Broader Role in Limiting HIV-1 Infection
16 Feb 2016
Biotron Anti-Viral Compounds to be Tested in USA for Activity Against Zika Virus
15 Jan 2016
Appendix 4C
15 Jan 2016
New Issue Announcement – Appendix 3B
12 Jan 2016
Biotron Limited Presents at Biotech Showcase 2016

2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
>>

Investor Centre

Investor Centre

© Biotron Limited 2016 ABN 60 086 399 144 Site updated 30 July 2019 Legal Notices and Privacy